期刊文献+

姜黄素逆转P-gp介导卵巢癌多药耐药机制的研究 被引量:10

Effect of curcumin on reverse P-gp mediated mechanism of multidrug resistance in ovarian cancer
原文传递
导出
摘要 目的探讨姜黄素对P糖蛋白(P—gP)介导的卵巢癌多药耐药的逆转作用及其可能机制。方法采用二苯基溴化四氮唑蓝(MTT)法检测人卵巢癌癌细胞株加药后的增殖,碘化丙啶(PI)染色法检测细胞凋亡率,western blot法检测P—Akt和P-gP的表达量。结果姜黄素合用顺铂处理细胞(OVCAR-3/DDP细胞株)48h,顺铂的浓度在0.05—5μg/ml时,加入姜黄素25μmol/L,耐药细胞生存率下降明显(P〈0.05),尤以顺铂0.25μg/ml和姜黄素25μmol/L作用时耐药细胞生存率下降最明显。单用顺铂组细胞的凋亡率为(13.2±2.5)%,采用在顺铂基础上联合使用姜黄素后细胞凋亡率为(21.8±3.5)%,与单独使用顺铂相比,顺铂与姜黄素联合使用诱导细胞凋亡的作用显著增强(P〈0.05)。与单用顺铂0.25μg/ml相比,联合使用姜黄素后p-Akt和P-gP的表达量明显降低(P〈0.05),2组间Akt的表达量差异无统计学意义(P〉0.05)。结论姜黄素不增加顺铂对OVCAR-3细胞毒性作用;对于OVCAR-3/DDP细胞株,姜黄素明显增加顺铂细胞毒性;姜黄素明显抑制了p-Akt和P—gP蛋白的表达。姜黄素可能通过抑制Akt信号通路降低P—gP的表达进而逆转多药耐药。 Objective To investigate the effects of curcumin on P glycoprotein (P-gp) reversal effect of ovarian cancer mediated muhidrug resistance and its possible mechanism. Methods For determination of drugs in vitro cytotoxicity by MT]" assay, apoptosis was detected by PI staining, expression of p-Akt and P-gp for detection by Western blot method. Re- suits Curcumin did not increase cisplatin cytotoxicity on OVCAR-3 ; for OVCAR-3/DDP cells, curcumin significantly in- creased the cytotoxieity of cisplatin;inhibition of expression of p-Akt and P-gp protein were inhibited by curcumin. Con- clusion Curcumin can inhibit Akt signaling pathway by decreasing the expression of P-gp and reversal of multidrug re- sistance.
出处 《中华全科医学》 2014年第6期932-934,共3页 Chinese Journal of General Practice
基金 2012年浙江省中医药科学研究基金计划(A类)(2012ZA053)
关键词 姜黄素 P糖蛋白 顺铂 多药耐药 逆转 Curcumin Pglycoprotein Cisplatin Multidrug resistance Reversal
  • 相关文献

参考文献19

  • 1Robella M, Vaira M, Marsanic P, et al. Treatment of peritoneal carcino- matosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy ( HIPEC ) [ J ]. Minerva Chir, 2014,69 ( 1 ) :27-35.
  • 2Zahedi P, De Souza R, Huynh L, et al. Combination drug delivery strat- egy for the treatment of muhidrug resistant ovarian cancer [ J ]. Mol Pharm,2011,8( 1 ) :260-269.
  • 3Adamus G, Choi D, Raghunath A, et al. Significance of Anti-retinal Autoantibodies in Cancer-associated Retinopathy with Gynecological Cancers[ Jl. J Clin Exp Ophthalmol,2013,4(6) :307.
  • 4Conde J,de la Fuente JM, Baptista PV. Nanomaterials for reversion of multidrug resistance in cancer: a new hope for an old idea [ J ]. Front Pharmaco1,2013,25 (4) : 134.
  • 5Nieto MR, Beduneau A, Pellequer Y, et al. Delivery of P-glycoprotein substrates using chemosensitizers and nanotechnology for selective and efficient therapeutic outcomes [ J ]. J Control Release, 2012,161 ( 1 ) : 50-61.
  • 6Rajasekaran M, Annaraj J. A lucid build-up of nanostructured curcu- min, quercetin and their interaction with DNA [ J ]. J Nanosci Nano- techno1,2014,14 ( 7 ) :4874-4879.
  • 7Cidado J, Park BH. Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy [ J ]. J Mammary Gland Biol Neoplasia, 2012,17 ( 3-4 ) : 205-216.
  • 8Li JC,Zhu HY, Chen TX, et al. Roles of mTOR and p-mTOR in gastro- intestinal stromal tumors[ J]. Asian Pac J Cancer Prev,2013,14(10) : 5925-5928.
  • 9张栋,孔德璇,和珍珍,瞿全新.PI3K/Akt信号转导通路与卵巢癌顺铂耐药相关性的研究[J].天津医药,2011,39(4):361-363. 被引量:11
  • 10Li YC, He SM,He ZX,et al. Plumbagin induces apoptotic and auto- phagic cell death through inhibition of the PI3 K/Akt/mTOR pathway in human non-small cell lung cancer cells [ J ]. Cancer Lett, 2014, 344(2) :239-259.

二级参考文献9

  • 1Brozovic A,Ambriovic-Ristov A,Osmak M.The relationship between cisplatin-induced reactive oxygen species,glutathione,and BCL-2 and resistance to cisplatin[J].Crit Rev Toxicol,2010,40(4):347-359.
  • 2Levine DA,Bogomolniy F,Yee CJ,et al.Frequent mutation of gene PI3KCA in ovarian and breast cancers[J].Clin Cancer Res,2005,11(8):2875-2878.
  • 3Balsam BR,Pei J,Mitsuuchi Y,et al.Frequent activation of Akt in non-small cekk lung carcinomas and preneoplastic bronchial lesions[J].Careimpgenesis,2004,25(11):2053-2059.
  • 4Noske A,Kaszubiak A,Weichert W,et al.Specific inhibition of AKT2 by RNA Interfeemce resμLts in reduction of ovarian cancer cell proliferation:Increased expression of AKT in advanced ovarian cancer[J].Concer Lea,2006,235(1):25-30.
  • 5Zhang HY,Zhang PN,Sun H.Aberration of the PI3K/AKT/mTOR signaling in epithelial ovarian cancer and its implication in cisplatin-based chemotherapy[J].Eur J Obstet Gynecol Reprod Biol,2009,146(1):81-86.
  • 6Peng DJ,Wang J,Zhou JY,et al.Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells[J].Biochem Biophys Res Commun,2010,394(3):600-605.
  • 7Page C,Lin HJ,Jiny,et al.Overexpression of Akt/Akt can modulate chemotherapy-induee apoptosis[J].Anticancer Res,2000,20 (1A):407-416.
  • 8Fraser M,Bai T,Tsang BK.Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phesphorylation and nuclear function[J].Int J Cancer,2008,122(3):534-546.
  • 9Weng D,Song X,Xing H,et al.Implication of the Akt2/survivin pathway as a critical target in paclitaxel treatment in human ovarian cancer cells[J].Cancer Lett,2009,273(2):257-265.

共引文献10

同被引文献175

引证文献10

二级引证文献55

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部